Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma

American Journal of Kidney Diseases

Volumn 57, Issue 2, 2011, Pages 300-303

  Herrington, William G ^a   Talbot, Denis C ^b   Lahn, Michael M ^c   Brandt, John T ^c   Callies, Sophie ^c   Nagle, Ray ^d   Winearls, Christopher G ^a   Roberts, Ian S D ^e  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antisense oligonucleotide; kidney injury; survivin

Indexed keywords

ATENOLOL; DACARBAZINE; IBUPROFEN; INTERFERON; LY 2181308; RAMIPRIL;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; FATIGUE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA; METASTASIS; MITOCHONDRION SWELLING; REGENERATION; SIDE EFFECT; THROMBOCYTOPENIA;

ACUTE KIDNEY INJURY; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 78751632457     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.09.024     Document Type: Article

References (12)

1. G. Ambrosini, C. Adida, and D.C. Altieri A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3 8 1997 917 921
2. D.C. Altieri Validating survivin as a cancer therapeutic target Nat Rev Cancer 3 1 2003 46 54
3. P. Lechler, X. Wu, and W. Bernhardt The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney Am J Pathol 171 5 2007 1483 1498
4. H. Doolittle, A. Morel, and D. Talbot Survivin directed anticancer therapies - a review of pre-clinical data and early phase clinical trials Eur Oncol 6 1 2010 10 14
5. D.C. Talbot, J. Davies, and S. Callies First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin [abstract 3518] J Clin Oncol 26 15S May 20 2008
6. R.S. Geary Antisense oligonucleotide pharmacokinetics and metabolism Expert Opin Drug Metab Toxicol 5 4 2009 381 391
7. D.C. Talbot, J. Davies, and A. Olsen Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies [abstract 3507] J Clin Oncol 27 15S May 20 2009
8. A. Levey, J. Bosch, J. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461 470
9. A.W. Tolcher, A. Mita, and L.D. Lewis Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin J Clin Oncol 26 32 2008 5198 5203
10. H. Izzedine, C. Isnard-Bagnis, and V. Launay-Vacher Gemcitabine-induced thrombotic microangiopathy: a systematic review Nephrol Dial Transplant 21 11 2006 3038 3045
11. M. Rowland, and T.N. Tozer Clinical PharmacokineticsConcepts and Applications 3rd ed. 1994 Lippincott Williams & Wilkins Philadelphia, PA
12. J.R. Lawrence, W.H. Steele, J.F. Stuart, C.A. McNeill, J.G. McVie, and B. Whiting Dose dependent methotrexate elimination following bolus intravenous injection Eur J Clin Pharmacol 17 5 1980 371 374